SOFAR S.p.A.   Report issue

For profit Phase 1 Phase 3 Phase 4
Founded: Firenze Italy (1968)
Status: Acquired by TransEnterix (2015)

Organization Overview

First Clinical Trial
2004
NCT00774007
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

SOFAR S.p.A.

Active Ingredients

Drugs in Phase 4 Trials (1)

lactobacillus casei (3 trials)

Drugs in Phase 3 Trials (1)

mesalamine (rowasa) (4 trials)

Drugs in Phase 1 Trials (1)

beclomethasone (vanceril) (1 trial)

Drugs in Other Trials (3)

bifidobacterium animalis (1 trial)

bifidobacterium bifidum (1 trial)

omeprazole (prilosec) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Colorectal Neoplasms (Phase 2)

Diverticular Diseases (Phase 3)

Diverticulum (Phase 3)

Irritable Bowel Syndrome (Phase 4)

Syndrome (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 11
  • # of Trial APIs: 6